SOURCE: NuLife Sciences, Inc.

NuLife Sciences, Inc. Logo

August 29, 2017 08:31 ET

NuLife Announces Second Round of Pre-Clinical Surgeries

Refining the Revolutionary Approach to Kidney Transplant

SAN CLEMENTE, CA--(Marketwired - August 29, 2017) - NuLife Sciences (OTCQB: NULF) through the company's wholly-owned subsidiary, NuLife BioMed, Inc., today announced it is initiating the second round of pre-clinical surgeries to refine the NuLife Technique, a means to potentially eliminate the need for organ or tissue matching between donor and recipient in organ transplants and the necessity for anti-rejection drugs after surgery.

The series of surgeries build upon each other, and are part of the pre-clinical trial of the NuLife Technique, which commenced on August 8th at Florida International University, to evaluate the NuLife process and prove that the NuLife Technique is viable and effective.

This surgery, which is being conducted by Doctors Juan Arenas and Tjasa Hranjec, will serve to confirm results seen in the first surgery, as well as an opportunity to fine tune the NuLife Technique. Juan Arenas, MD, FACS, MBA, is a board-certified transplant surgeon, Director of the Solid Organ Transplant Institute, and the Chair of Solid Organ Transplant at Memorial Regional Hospital in Hollywood, Florida. Prior to this role, he served as the Chief of the Division of Surgical Transplantation at the University of Texas (UT) Southwestern Medical Center for the past 10 years. Tjasa Hranjec, MD, MS-CR is a Board certified trauma/critical care and transplant surgeon, the director of the Transplant Intensive Care Unit at the Memorial Regional Hospital in Hollywood.

"We are excited that the team was able to move into the second round as quickly as they have," said John Hollister, NuLife Sciences Chief Executive Officer. "We anticipate being able to review the results from the first round in the coming two weeks and report them at an upcoming scientific meeting."

About NuLife Sciences

NuLife Sciences Inc. (OTCQB: NULF) is a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including transplantation/regenerative medicine/cell therapy/organ and tissue transplants. Through its wholly-owned subsidiary NuLife BioMed, it is currently working on advancing human organ transplant technology based upon a patent protected and unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal studies on its pathway to commercialization. For more information please visit

Safe Harbor

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, many of which are beyond the Company's control. The Company's actual results could differ materially and adversely from those anticipated in such forward-looking statements as a result of certain factors, including those set forth below and elsewhere in this press release. All statements, other than statements of historical facts, included in this press release regarding the Company's growth strategy, future operations, financial position, estimated revenue or losses, projected costs, prospects and plans and objectives of management are forward-looking statements. When used in this press release, the words "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," "plan" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements or other information contained herein. Potential investors should not place undue reliance on these forward-looking statements. Although the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements in this press release are reasonable, the Company cannot assure potential investors that these plans, intentions or expectations will be achieved. The Company discloses important factors that could cause the Company's actual results to differ materially from its expectations under "Risk Factors" and elsewhere in this press release. These cautionary statements qualify all forward-looking statements attributable to the Company or persons acting on its behalf.

Contact Information